Eli Lilly’s retatrutide, a triple agonist already covered in this site’s guide to the drug, posted its first Phase 3 obesity results in May 2026. The TRIUMPH-1 trial found that participants on the highest dose lost close to a third of their body weight over two years — among the largest average weight-loss figures reported in a placebo-controlled peptide-drug trial to date. Retatrutide remains investigational, with no FDA decision yet, but the results give the first real look at how the drug performs outside early-phase testing.

What TRIUMPH-1 Tested

TRIUMPH-1 was a randomized, double-blind, placebo-controlled Phase 3 trial (registered as NCT05929066) enrolling 2,339 adults with obesity or overweight and at least one weight-related condition, but without diabetes. Participants were assigned to one of three retatrutide doses — 4 mg, 9 mg, or 12 mg weekly injections — or placebo, and followed for up to 104 weeks.

The Results by Dose

At 80 weeks, average weight loss was 19.0% on the 4 mg dose, 25.9% on 9 mg, and 28.3% on the 12 mg dose. Patients who stayed on the highest dose through 104 weeks averaged 30.3% weight loss, or about 85 pounds. Lilly has said full data will be presented at the American Diabetes Association’s Scientific Sessions, with additional Phase 3 results expected later in 2026 from TRIUMPH-2 (in people with type 2 diabetes) and TRIUMPH-3 (in people with established cardiovascular disease).

How Retatrutide Differs From Approved GLP-1 Drugs

Retatrutide is a triple agonist, activating receptors for GLP-1, GIP, and glucagon, rather than the single GLP-1 target of semaglutide or the dual GLP-1/GIP mechanism of tirzepatide. The added glucagon activity is thought to increase energy expenditure and reduce liver fat on top of the appetite-suppressing effects shared across the class — a proposed explanation for the larger average weight-loss figures seen so far, though the mechanism hasn’t been definitively confirmed through head-to-head human trials.

Regulatory Status: Still Investigational

Retatrutide is not FDA-approved for any use. TRIUMPH-1 is a pivotal trial intended to support a future approval application, but Lilly has not announced a submission date, and the FDA review process, discussed in this site’s guide to how a drug moves from trial to approval, typically takes many months once an application is filed. Nothing about these results changes retatrutide’s current unapproved, investigational status.

Safety Signals So Far

Lilly’s release characterized the safety profile as consistent with the GLP-1 drug class, with gastrointestinal side effects — nausea and diarrhea — the most commonly reported issue and the main driver of trial discontinuations, concentrated during the dose-escalation phase. No new or unexpected safety signals were reported, though Phase 3 safety data at this stage still reflects a controlled trial population followed for a defined period, not the long-term, real-world safety picture that only emerges after a drug reaches the broader market.

What Comes Next

Two more pivotal trials, TRIUMPH-2 and TRIUMPH-3, are expected to report later in 2026, and will show how retatrutide performs in people with diabetes and cardiovascular disease specifically — populations distinct from the TRIUMPH-1 cohort. Until an FDA decision is made, retatrutide should be treated as an investigational compound, not an available treatment option, regardless of how it is discussed or marketed in other online research-chemical contexts.